• Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds

    Bio-IT World | The mood at this year's J.P. Morgan Healthcare Conference signals a dramatic shift for biopharma dealmaking, with industry leaders projecting 2026 could eclipse last year's surging merger and acquisition activity. During an Endpoints News panel discussion, senior executives from AbbVie, Amgen, and Merck expressed confidence that favorable market conditions and breakthrough science are converging to create what one panelist called "a renaissance moment" for the sector.

    Jan 23, 2026

  • Improved Drug Safety Needs Better Data Before AI

    Bio-IT World | Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process.

    Jan 23, 2026

  • AI in Pharma: Progress Made, But Data Challenges Persist

    Bio-IT World | The pharmaceutical industry’s approach to artificial intelligence is maturing, with companies increasingly focused on innovation rather than mere efficiency gains. However, significant hurdles around data quality and workforce training continue to impede progress.

    Jan 20, 2026